The programme spans multiple trials targeting distinct endpoints: On 21 May 2026 Eli Lilly reported topline results from TRIUMPH-1, the pivotal Phase 3 obesity trial and the programme's first Phase 3 efficacy readout: in 2,339 adults, mean weight loss at the 80-week primary endpoint reached 19.0% (4mg), 25.9% (9mg), and 28.3% (12mg) versus 2.2% for placebo (Eli Lilly investor release
On the manufacturing and investment front, Amgen committed to major US expansions, including a $650 million upgrade of its Puerto Rico biologics manufacturing network expected to create hundreds of jobs and bolster supply chain resilience, alongside ongoing multi-hundred-million-dollar facility builds and innovation centers in North Carolina, Ohio, and California
both async and synchronous (video) consultation options depending on state
Here, we analyze existing data around immunological risks, complications, and consequences of this disease, particularly in relation to COVID-19 infections and treatment
